These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34530381)

  • 61. Rare diseases and orphan drugs: Latvian story.
    Logviss K; Krievins D; Purvina S
    Orphanet J Rare Dis; 2014 Sep; 9():147. PubMed ID: 25231378
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Orphan drugs: the regulatory environment.
    Franco P
    Drug Discov Today; 2013 Feb; 18(3-4):163-72. PubMed ID: 22981668
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [European incentives for orphan medicinal products].
    Enzmann H; Lütz J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Orphanage at the FDA.
    Chen E
    J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134
    [No Abstract]   [Full Text] [Related]  

  • 65. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M; Kubácková K; Palágyi M; Smíd M
    Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Orphan drug development in alpha-1 antitypsin deficiency.
    Trudzinski FC; Presotto MA; Buck E; Herth FJF; Ries M
    Sci Rep; 2022 Sep; 12(1):15497. PubMed ID: 36109566
    [TBL] [Abstract][Full Text] [Related]  

  • 67. 1992 Le Tourneau Award. Problems with pharmaceutical regulation in the United States. Drug lag and orphan drugs.
    Henry V
    J Leg Med; 1993 Dec; 14(4):617-39. PubMed ID: 8308452
    [No Abstract]   [Full Text] [Related]  

  • 68. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
    Tiwari J
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):63-7. PubMed ID: 25497996
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
    Valverde AM; Reed SD; Schulman KA
    Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Exploring the Potential Challenges for Developing Generic Orphan Drugs for Rare Diseases: A Survey of US and European Markets.
    Murthannagari VR; Gonna Nandhi Krishnan G; Manu KV; Jayachandraiah CT; Mandadhi Rajendra PK; Ahmed SS
    Value Health Reg Issues; 2023 May; 35():87-94. PubMed ID: 36921379
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Preserving an Incentive for Global Health R&D: The Priority Review Voucher Secondary Market.
    Robertson AS
    Am J Law Med; 2016 May; 42(2-3):524-542. PubMed ID: 29086641
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy Experience.
    Lomash RM; Shchelochkov O; Chandler RJ; Venditti CP; Pariser AR; Ottinger EA;
    Hum Gene Ther; 2023 Mar; 34(5-6):217-227. PubMed ID: 36694456
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Minor Use and Minor Species Animal Health Act: past, present, and future.
    Haley CJ
    Food Drug Law J; 2006; 61(1):13-43. PubMed ID: 16838456
    [No Abstract]   [Full Text] [Related]  

  • 75. Adoption agents.
    Wapner J
    Sci Am; 2010 Jun; 302(6):19-20. PubMed ID: 20521471
    [No Abstract]   [Full Text] [Related]  

  • 76. Precision Medicines' Impact on Orphan Drug Designation.
    Mueller CM; Rao GR; Miller Needleman KI
    Clin Transl Sci; 2019 Nov; 12(6):633-640. PubMed ID: 31297924
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Legal and regulatory aspects of orphan drugs.
    Shani S; Yahalom Z
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():110-5. PubMed ID: 24380129
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
    Oo C; Rusch LM
    J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513
    [No Abstract]   [Full Text] [Related]  

  • 79. The economics of priority review vouchers.
    Dimitri N
    Drug Discov Today; 2010 Nov; 15(21-22):887-91. PubMed ID: 20732445
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.
    Lutz T; Lampert A; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2016 May; 11(1):60. PubMed ID: 27176041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.